Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 36 % of short-term debt in 2024; threshold 65 %.
-
Busy address KBO
70 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2024
Horus Pharma Belux from Anderlecht, company number BE0633793446, closed financial year 2024 with a result of € 161,688 after tax. For that financial year Horus Pharma Belux recorded a gross margin of € 1.9 million and equity of € -3.2 million. Compared with financial year 2023, the result moved from € 106,122 to € 161,688. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 1, 2025.
€ -3.2 million
▲ € 161,688 vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 161,688
▲ 52% vs 2023
Profit after tax over the fiscal year.
€ 122,002
▲ 18% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € -3.5 million.
People and assets in 2024
13
▼ 1 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 1.7 million
▲ 12% vs 2023
€ 128,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 695
▼ 59% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 2.4 million
▼ 2% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 305,192
▼ 12% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € 1,044,106 | € 1,446,402 | € 1,693,627 | € 1,927,040 | ▲ 14% |
| Profit after taxes | € 67,055 | € 52,468 | € 106,122 | € 161,688 | ▲ 52% |
| Equity | € -3,539,334 | € -3,486,865 | € -3,380,743 | € -3,219,055 | ▲ € 161,688 |
| Total debts | € 6,670,070 | € 6,940,405 | € 6,636,214 | € 6,546,474 | ▼ 1% |
| Cash | € 103,908 | € 150,750 | € 103,261 | € 122,002 | ▲ 18% |
| Retained profit | € -3,839,334 | € -3,786,865 | € -3,680,743 | € -3,519,055 | ▲ € 161,688 |
| Balance sheet total | € 3,130,737 | € 3,453,539 | € 3,255,470 | € 3,327,419 | ▲ 2% |
| Employees (FTE) | 9.3 | 14 | 14 | 13 | ▼ 1 |
Key figures of Horus Pharma Belux, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to Horus Pharma Belux?
What happened at Horus Pharma Belux in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- CLARET CLAUDE stepped down as director. NBB
- New annual accounts for financial year 2024: profit of € 161,688 (▲ 52% vs 2023). filed late Source: NBB ↗
- HORUS PHARMA SAS stepped down as director. NBB
- CLARET CLAUDE became a director. NBB
- HORUS PHARMA SAS became a director. NBB
- Start of the company according to the CBE. KBO
- New establishment in Anderlecht. KBO
In short
From € 67,055 profit in 2021 to € 161,688 profit in 2024.
Paid € 19,533 in corporate taxes since 2021.
Best year ever: 2024, with € 161,688 profit.
On average € 148,200 of value added per employee in 2024.
A new publication or filing at Horus Pharma Belux? We notify you, reason included.
Follow Horus Pharma BeluxDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2024 annual accounts
CLARET CLAUDE
Director
since 2021 · until 2027
HORUS PHARMA SAS
Director
since 2018 · until 2024
Establishments
Establishment units
Physical locations of this company
Lennikse Baan 451
1070 Anderlecht
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 70 companies are registered at this address.
All companies at this address →FISCHBEIN
€ 13.9 million revenue · 2025
HAIER BENELUX
€ 16.1 million revenue · 2025
PIRELLI TYRES BELUX
€ 3.6 million revenue · 2025
Ferring
€ 21.4 million revenue · 2023
HEALTH DATA MANAGEMENT PARTNERS
€ 1.5 million gross margin · 2025
+65 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0633.793.446
- VAT number
- BE 0633.793.446
- Registered office
- Lennikse Baan 451, 1070 Anderlecht
- Names & denominations
- Horus Pharma Belux
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 13 July 2015
- Peppol
- Active · Active since 15 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Detailhandel in farmaceutische producten